Why Dyax Will Dominate Biotech News on Wednesday
Dyax is almost certain to dominate the biotech news flow on Wednesday, after it announced positive trial data on Tuesday evening.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 269Ebola Finances Coming Back in the News
Within the past week, two Ebola-related companies are showing renewed optimism for their positions, whether it is securing a contract or raising capital.
Are Auspex Shareholders Getting Enough in the Buyout?
News broke Monday that Teva Pharmaceutical Industries will acquire Auspex Pharmaceuticals. Existing investors will be wondering if they are getting enough in this buyout.
Can Boston Scientific Keep Its Turnaround Gains Going?
Boston Scientific shares are up almost 50% in the past six months, and the stock has more than doubled from two years ago. The question is whether this turnaround can keep turning around.
Why a PBM Acquisition Is Taking UnitedHealth to All-Time Highs
Catamaran, a provider of pharmacy benefit management services and technology solutions, announced Monday morning that it has agreed to merge with OptumRx.
RBC Has 4 Biotech Stocks to Buy After Massive Pullback
In a new report from RBC, while they think the selling and profit taking in biotechs could go on, they also hold fast that industry fundamentals are still very positive.
UBS Raises Price Targets on 4 Top Health Care Providers
If there has been one group stocks that has delivered for investors this year it has been the managed care organizations (MCO) that are the top health care providers in the United States.
Major Biotech Is So-So for Short Sellers
The March 13 short interest data in top biotechs have been compared with the end of February figures, and across the board all the selected stocks have seen their short interest increase.
Why Deutsche Bank Says to Buy Gilead and Vertex Pullbacks
Deutsche Bank says that investors have misread the current instances floating around two leading biotech stocks, and they both should be bought now on any continuing weakness.
Can MEI Pharma Survive?
After MEI Pharma cratered in the wake of disappointing results from one of its studies, analysts are making their calls on where the stock looks to go from here.
The Top 5 Biotech Stocks of 2015 — Average Gains So Far Over 200%
ThinkstockThe multiyear run in major biotech stocks has not let up in 2015. Most of the large and mid-cap stocks in the industry are higher, but the smaller and lesser known names have also…
4 Pharmaceutical Stocks to Buy for Outperformance in 2015
A new research report from the technical team at RBC cites Bristol-Myers Squibb, Eli Lilly, Mylan and Perrigo as stocks that may continue to show sector leadership.
Alzheimer’s Drug Could Be Instant Blockbuster for Biogen Idec
Friday morning, Biogen Idec announced positive results related to its Alzheimer's study. Any real Alzheimer's drug certainly would make the blockbuster category.
How Large Is Prothena’s Market Opportunity?
Prothena has announced positive results from a Phase 1 study of a monoclonal antibody for the potential treatment of Parkinson's disease and other related synucleinopathies.
How the Tekmira Secondary Offering Could Help the Company
Tekmira Pharmaceuticals, one of the top names in the Ebola drug arena, is now about to raise a significant amount of capital in a secondary offering.